about
Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort studyA randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.European School of Internal Medicine (ESIM) in Brighton: experiences and reflections.The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic valueExpression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys--a preliminary pilot studyC1q complement component and -antibodies reflect SLE activity and kidney involvementProtocol biopsy of a transplanted kidney as a tool for monitoring adequacy of immunosuppressive therapy: 10 years of experience from a single transplant centerComplement system in SLE as a target for antibodiesThe levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value
P50
Q36321563-4B23B2D4-AA09-4A6A-AC0A-1820E8C0650FQ37604531-7B0FCB90-33B0-415C-B96C-76BA7809D7D2Q51033740-68382AD1-79C0-48A6-87E5-9D67DB5A685FQ79356290-A3447AE3-F755-4412-B35B-A4F9D6EFE6D0Q81422120-FAAB54D9-ED6C-4B3F-A7E5-4DD24806ABB2Q81538418-79C646DD-3381-472D-BF32-44DA4A493B72Q84409727-A6DD20EC-B7E0-4CF0-8981-9C12EF7F3839Q85268913-B7D017F4-EE38-459B-B0B5-50FA5D9275B6Q88118786-BE03F3C4-C1E0-45C6-BD11-4C46380DFCCB
P50
description
investigador
@es
researcher
@en
name
Hana Ciferská
@en
Hana Ciferská
@nl
type
label
Hana Ciferská
@en
Hana Ciferská
@nl
prefLabel
Hana Ciferská
@en
Hana Ciferská
@nl
P31
P496
0000-0002-8928-8543